scholarly journals Postmenopausal Women with HR +/ HER2 – Early Breast Cancer, 1–3 Positive Nodes, and a Low Risk of Recurrence Can Safely Forego Chemotherapy

2021 ◽  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Low Risk ◽  
Risk Of Recurrence

DOES ONE SIZE FIT ALL? COST UTILITY ANALYSES OF ALTERNATIVE MAMMOGRAPHIC FOLLOW-UP SCHEDULES, BY RISK OF RECURRENCE

2015 ◽  
Vol 31 (5) ◽  
pp. 281-288 ◽  
Author(s):  
Taryn Bessen ◽  
Dorothy M.K. Keefe ◽  
Jonathan Karnon
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Poor Prognosis ◽  
Controlled Trial ◽  
Discrete Event ◽  
Prognostic Index ◽  
Cost Effective ◽  
Risk Of Recurrence

Objectives: International guidelines recommend annual mammography after early breast cancer, but there is no randomized controlled trial evidence to support this schedule over any other. Given that not all women have the same risk of recurrence, it is possible that, by defining different risk profiles, we could tailor mammographic schedules that are more effective and efficient.Methods: A discrete event simulation model was developed to describe the progression of early breast cancer after completion of primary treatment. Retrospective data for 1,100 postmenopausal women diagnosed with early breast cancer in South Australia from 2000 to 2008 were used to calibrate the model. Women were divided into four prognostic subgroups based on the Nottingham Prognostic Index of their primary tumor. For each subgroup, we compared the cost-effectiveness of three different mammographic schedules for two different age groups.Results: Annual mammographic follow-up was not cost-effective for most postmenopausal women. Two yearly mammography was cost-effective for all women with excellent prognosis tumors; and for women with good prognosis tumors if high compliance rates can be achieved. Annual mammography for 5 years and 2 yearly surveillance thereafter (a mixed schedule) may be cost-effective for 50- to 69-year-old women with moderate prognosis tumors, and for women aged 70–79 years with poor prognosis tumors. For younger women with poor prognosis tumors, annual mammography is potentially cost-effective.Conclusions: Our results suggest that mammographic follow-up could be tailored according to risk of recurrence. If validated with larger datasets, this could potentially set the stage for personalized mammographic follow-up after breast cancer.

Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 518-518 ◽  
Author(s):  
P. E. Lonning ◽  
J. Geisler ◽  
L. E. Krag ◽  
L. Ottestad ◽  
Y. Bremnes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Low Risk ◽  
Controlled Study

Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 518-518 ◽  
Author(s):  
P. E. Lonning ◽  
J. Geisler ◽  
L. E. Krag ◽  
L. Ottestad ◽  
Y. Bremnes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Low Risk ◽  
Controlled Study
Sign in / Sign up

Export Citation Format

Share Document